Close Menu

NEW YORK (GenomeWeb) – Guardant Health announced today a multiyear agreement with AstraZeneca to develop blood-based companion diagnostic tests for drugs in the pharma firm's oncology portfolio.

Under the terms of the agreement, Guardant is developing and pursuing FDA approval for a companion test that will help identify non-small cell lung cancer patients likely to respond to Tagrisso (osimertinib), AstraZeneca’s third-generation EGFR inhibitor.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
12
Sponsored by
Truvian

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.